Chemokines and their receptors direct cell migration in homeostatic and inflamed conditions, thus they are major players in key events of immune-mediated disorders. Indeed, much evidence indicates a non-redundant role of the chemokine system in several human diseases, ranging from classical immune-mediated pathologies, such as autoimmune and allergic diseases and transplant rejection, to neoplastic and vascular diseases. Increasing emerging evidence suggests the possible role of chemokines as biomarkers for monitoring disease activity, predicting relapses, monitoring surgical and pharmacological therapy and for providing prognostic indications. Several methods are now available for the detection and measurement of chemokines and their receptors in body fluids and tissues. The advantage of these assays is that they may be used in clinical laboratory and are directly applicable for biomedical diagnosis, representing a powerful tool which could dramatically improve screening, diagnosis and monitoring of diseases in the very near future.
Chemokines and their receptors direct cell migration in homeostatic and inflamed condition, thus they are major players in key events of immunemediated disorders. These molecules are a family of 42 structurally and functionally related small secreted proteins whose main biological function is leukocyte recruitment (1) (2) , and which are divided into four subfamilies (CC, CXC, CX3C and C) according to the position of the first two cysteins residues and acting on different leukocytes subtypes: neutrophils, Thl and NK cells for CXC chemokines, monocytes for mainly CC chemokines.
Chemokines as human disease biomarkers
Since they exert a critical role in the pathogenesis and development of a large range of human diseases, a possible relevance of chemokines and their receptors as biomarkers is an emerging concept in clinical practice. Although chemokines still present some limitations as markers for the diagnosis and screening of human diseases (they are rarely organ specific and display a pleiotropic activity), increasing emerging evidence suggests the possible role of chemokines as biomarkers for monitoring disease activity, predicting relapses, monitoring surgical and pharmacological therapy and for providing prognostic indications. Much evidence, as described in Table I , indicates a non-redundant role of chemokine system in several human diseases, ranging from classical immune-mediated pathologies such as autoimmune and allergic diseases and transplant rejection to neoplastic and vascular disease (3) (4) (5) (6) (7) (8) (9) (10) (11) . Differently from other canonical clinical markers of disease activity, chemokine investigation can be more interesting for assessing the activity of a disease and its prognosis. Moreover, chemokine measurement can be a very useful tool to categorize patients entering in clinical trials, to select the most suitable therapeutical agents and to monitor the efficacy and tolerance of therapies (12) .
Chemokine measurement in clinical laboratory practice
Several methods are now available for the detection and measurement of chemokines and their receptors in body fluids and tissues and these are described in Table II (13) , while the general principle ofthese methods, and their advantages and limits in clinical use are described in Table Ill . The panel of chemokine measurement assays includes bioassays, immunoassays, molecular biology techniques, flow cytometry, and array systems (14) . Bioassays for chemokine receptors are sensitive in the picogram range but they lack specificity, since the promiscuous binding of different chemokines to the same receptor requires neutralization with a chemokine specific antibody to confirm the identity of the measured receptor. This is the reason why this kind of assay is mainly used for validation of results obtained by other chemokine detection methods (15) . Immunoassays are the most used method to measure chemokines for their ease of performance and reproducibility (coefficient of variation 5-10%), and their high sensitivity (10 pg/mL) due to the utilization of specific monoclonal antibody.
The two most utilized assays are Enzymelinked-immunosorbent-assay (ELISA) and radioimmunoassay (RIA). The advantages of these methods are that they are very rapid and specific for the molecules analyzed, but they do not identify functional molecules. A large range of ELISA assay kits for all the chemokine and chemokine receptor families are commercially available and they are provided by several different manufacturers. Results obtained using kits from different manufacturers have shown slight differences but well within acceptable range of variance. This variability may be due to differences in specificity and sensibility of the unique monoclonal antibodies employed in each kit. Variability between ELISA kits may also be due to denaturation of the recognized epitope within the chemokine, fragmentation of the chemokines following enzymatic cleavage, binding of the chemokine to undefined ligands, and recognition to precursors form of chemokines which would interfere with their measurements. Another immunoassay, ELISPOT, is a powerful tool for detecting and analyzing individual cells that secrete a particular chemokine in vitro, measuring the chemokine-producing cell frequency. The advantage of ELISPOT is that it is more sensitive than classical ELISA, having a limit of detection (15) . Since chemokines exert their function in a local and paracrine way, their circulating level in biological fluid are very low and difficult to detect. For this reason immunoistochemichal methods of in situ hybridization have been developed to detect chemokine tissue distribution and production, allowing to combine double and triple labeling for the identification of the phenotype of chemokine producing or receptor expressing cells in the tissue context. Tissue chemokine production can also be measured at mRNA level, by molecular biology methods such as RT-PCR and Quantitative Real Time PCR, or Microarray DNA Chip for a large scale analysis (16) . These methods are the most precise but for this reason they are also probably the most expensive, so that they are not commonly used in routine detection analysis but only for validation in specific cases. RT-PCR is a semi-quantitative assay with a high sensitivity and both intra-assay and inter-assay variability below 5%. This is an end point analysis, thus it provides only semi-quantitative results, because little variation of DNA amplification efficacy can result in dramatic changes in product yields (15) . To overcome this difficulty, Real Time quantitative RT-PCR was developed, showing a very high sensivity (below 60 cDNA moleculesl 10 ul reaction) and an intra-assay and inter-assay variability below 0.6 log units. On the contrary, a widely used technique for chemokine measurement is flow cytometry analysis, which allows to evaluate the chemokine production and the simultaneous phenotypic characterization of different cell populations. Similarly to ELISA assay, a large panel of anti-chemokine and anti-chemokine receptor antibodies are commercially available, and the sensitivity and specificity of this assay depend on the different manufacturer. Generally, these antibodies are monoclonal and very specific, with little or no cross-reactivity, but in order to improve the specificity of the assay, a negative control with an irrelevant epitope antibody is performed in parallel with the analyzed sample. The average range of sensitivity of these antibodies is 2-10 ug/ml. to detect the presence of 1 ug/ mL of target molecule. Since the regulation and the biological activity of chemokines represent a complex system, the ideal approach should be a combination of two or more assays, such as RT-PCR (which gives precise information at the mRNA level) associated to ELISA (which measures the protein molecule) or in situ hybridization (which localizes the chemokine or the receptor in the tissue context) (15) . In this context, another recent approach has been developed in order to analyze simultaneously the production of a large range of chemokines. This multiplex assay is based on an array system and on the multiplexing technology of Luminex Corp, using polystyrene beads dyed with different ratios of spectral distinct fluorophores, conjugated with monoclonal antibodies specificfor target chemokines, allowing the simultaneous measurement of multiple chemokines in a single sample (17) . The advantage of this approach is to be flexible and multipotential, giving a broad spectrum of information on a profile of chemokine production rather than only one by a single sample. The Luminex Technology has the advantage of being very sensitive, with a limit detection of 1 pg/ml. or 10 pg/mL if the analyte is measured in cell supernatant or serum, respectively. This assay can be considered very specific, with a cross reactivity which is negligible, and far under the under limit of 5%, and very precise, with an intra assay CV in the range of 5-7% and inter-assay CV in the range of 10-15%. This kind of multiplexed assay has recently been also applied to protein analysis, by means of protein biochip systems. The chip systems allows several tests to be performed simultaneously without dividing the original patient sample. The great potential of such miniaturized and multiplexed immunoassays is suggested by the definition a "lab on a chip device", allowing a great deal of information to be obtained from a single sample (18) . One of the most significant examples in this context is the rnulti-analyte biochip array technology developed by Randox (Crumlin, UK). This is an immune-based technology consisting of competitive, sandwich and antibody capture immunoassay coupled to chemioluminescence to detect and measure signals from the full array of tests on each chip (19) (20) . This assay can be a good analytic tool because it is very sensitive, with a measurement range of 500-1000 pg/mL and a limit detection of 0.4-1 pg/mL, and precise, with an intra-assay CV and inter-assay CV in the range of 5-8%. The advantage of these assays is that they may be used in clinical laboratories and are directly applicable for biomedical diagnosis, representing a powerful tool which could dramatically improve screening, diagnosis and monitoring of diseases in the very near future.
In conclusion, chemokines and chemokine receptors are major players in the pathogenensis and in the development of several human diseases. For this reason, measurement of chemokines and their receptors is an increasing and important aspect for monitoring the clinical progression of a disease, the efficacy of a surgical and pharmacological therapy, and, in an increasing number of diseases, to give additional information about the disease prognosis. In this context, chemokines and their receptors can be considered new biomarkers for the evaluation and the monitoring of diseases, representing a potential and useful tool in clinical laboratory practice.
